

GENOMIC HEALTH INC  
Form 8-K  
May 24, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **May 24, 2011**

**GENOMIC HEALTH, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or Other Jurisdiction of  
Incorporation)

**000-51541**

(Commission File Number)

**77-0552594**

(I.R.S. Employer  
Identification No.)

**301 Penobscot Drive**  
**Redwood City, California**  
(Address of principal executive offices)

**94063**  
(Zip Code)

**(650) 556-9300**

(Registrant's telephone number,  
including area code)

Edgar Filing: GENOMIC HEALTH INC - Form 8-K

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))
-

**Item 8.01 Other Events.**

On May 24, 2011, Genomic Health, Inc. issued a press release announcing positive preliminary results from the Eastern Cooperative Oncology Group validation study of Genomic Health's *Oncotype DX* breast cancer assay for patients with ductal carcinoma in situ of the breast. The full text of the press release is furnished as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) **Exhibits**

99.1 Press release issued by Genomic Health, Inc. dated May 24, 2011.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 24, 2011

GENOMIC HEALTH, INC.

By:

/s/ Dean L. Schorno  
Dean L. Schorno  
Chief Financial Officer

**GENOMIC HEALTH, INC.**

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release issued by Genomic Health, Inc. dated May 24, 2011.